Cardioprotection by controlling hyperamylinemia in a "Humanized" diabetic rat model

Journal of the American Heart Association

Volumn 3, Issue 4, 2014, Pages

  Despa, Sanda ^a   Sharma, Savita ^a   Harris, Todd R ^b   Dong, Hua ^b   Li, Ning ^c   Chiamvimonvat, Nipavan ^c,d   Taegtmeyer, Heinrich ^e   Margulies, Kenneth B ^f   Hammock, Bruce D ^b   Despa, Florin ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Amyloid; Calcium; Circulation; Diabetes mellitus; Heart diseases

Indexed keywords

1 (1 ACETYPIPERIDIN 4 YL) 3 ADAMANTANYLUREA; AMYLIN; CALCIUM ION; EICOSANOID ACID; FATTY ACID; HYDROLASE INHIBITOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 1-(1-ACETYL-PIPERIDINE-4-YL)-3-ADAMANTAN-1-YL-UREA; ADAMANTANE; CALCIUM; EPOXIDE HYDROLASE; ICOSANOID; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CELL; CALCIUM CELL LEVEL; CALCIUM METABOLISM; CARDIOTOXICITY; CELL LYSATE; CONTROLLED STUDY; DISORDERS OF HORMONE METABOLISM; DRUG MECHANISM; FATTY ACID BLOOD LEVEL; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE DILATATION; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HORMONE INHIBITION; HORMONE RELEASE; HUMAN; HUMAN TISSUE; HYPERAMYLINEMIA; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; SARCOLEMMA; TREATMENT DURATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CARDIOMEGALY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HEART; IMPAIRED GLUCOSE TOLERANCE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS; PANCREAS ISLET BETA CELL; TRANSGENIC ANIMAL; ULTRASTRUCTURE;

ADAMANTANE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CALCIUM; CARDIOMEGALY; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; EICOSANOIDS; EPOXIDE HYDROLASES; HEART; HUMANS; INSULIN-SECRETING CELLS; ISLET AMYLOID POLYPEPTIDE; MYOCARDIUM; MYOCYTES, CARDIAC; OBESITY; OXIDATIVE STRESS; PANCREAS; PREDIABETIC STATE; RATS; SARCOLEMMA; UREA;

EID: 84939460552     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001015     Document Type: Article

References (45)

1. Biddinger SB, Kahn CR. From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol. 2006;68:123-158.
2. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009;301:1547-1555.
3. Lopaschuk GD. Metabolic abnormalities in the diabetic heart. Heart Fail Rev. 2002;7:149-159.
4. Peterson LR. Obesity and insulin resistance: effects on cardiac structure, function, and substrate metabolism. Curr Hypertens Rep. 2006;8:451-456.
5. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Endocr Metab Disord. 2010;11:31-39.
6. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation. 2002;105:1727-1733.
7. Guha A, Harmancey R, Taegtmeyer H. Nonischemic heart failure in diabetes mellitus. Curr Opin Cardiol. 2008;23:241-248.
8. Despa S, Margulies KB, Chen L, Knowlton AA, Havel PJ, Taegtmeyer H, Bers DM, Despa F. Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: a study in humans and rats. Circ Res. 2012;110:598-608.
9. Gong W, Liu ZH, Zeng CH, Peng A, Chen HP, Zhou H, Li LS. Amylin deposition in the kidney of patients with diabetic nephropathy. Kidney Int. 2007;72:213-218.
10. Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 2011;91:795-826.
11. Johnson KH, O'Brien TD, Jordan K, Westermark P. Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells. Am J Pathol. 1989;135:245-250.
12. Enoki S, Mitsukawa T, Takemura J, Nakazato M, Aburaya J, Toshimori H, Matsukara S. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1992;15:97-102.
13. Westermark GT, Steiner DF, Gebre-Medhin S, Engstrom U, Westermark P. Pro islet amyloid polypeptide (ProIAPP) immunoreactivity in the islets of Langerhans. Ups J Med Sci. 2000;105:97-106.
14. Gurlo T, Ryazantsev S, Huang CJ, Yeh MW, Reber HA, Hines OJ, O'Brien TD, Glabe CG, Butler PC. Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol. 2010;176:861-869.
15. Lukinius A, Wilander E, Westermark GT, Engstrom U, Westermark P. Colocalization of islet amyloid polypeptide and insulin in the β-cell secretory granules of the human pancreatic islets. Diabetologia. 1989;32:240-244.
16. Wiltzius JJ, Sievers SA, Sawaya MR, Eisenberg D. Atomic structures of IAPP (amylin) fusions suggest a mechanism for fibrillation and the role of insulin in the process. Protein Sci. 2009;18:1521-1530.
17. Luca S, Yau WM, Leapman R, Tycko R. Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. Biochemistry. 2007;46:13505-13522.
18. Engel MF, Khemtemourian L, Kleijer CC, Meeldijk HJ, Jacobs J, Verkleij AJ, de Kruijff B, Killian JA, Hoppener JW. Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane. Proc Natl Acad Sci USA. 2008;105:6033-6038.
19. Janciauskiene S, Ahren B. Fibrillar islet amyloid polypeptide differentially affects oxidative mechanisms and lipoprotein uptake in correlation with cytotoxicity in two insulin-producing cell lines. Biochem Biophys Res Commun. 2000;267:619-625.
20. Zraika S, Hull RL, Udayasankar J, Aston-Mourney K, Subramanian SL, Kisilevsky R, Szarek WA, Kahn SE. Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis. Diabetologia. 2009;52:626-635.
21. Westwell-Roper C, Dai DL, Soukhatcheva G, Potter KJ, van Rooijen N, Ehses JA, Verchere CB. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J Immunol. 2011;187:2755-2765.
22. Jackson K, Barisone GA, Diaz E, Jin LW, DeCarli C, Despa F. Amylin deposition in the brain: a second amyloid in Alzheimer's disease? Ann Neurol. 2013;74:517-526.
23. Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K, Copeland RJ, Despa F, Hart GW, Ripplinger CM, Bers DM. Diabetic hyperglycemia activates CaMKII and arrhythmias by O linked glycosylation. Nature. 2013;502:372-376.
24. Guglielmino K, Jackson K, Harris TR, Vu V, Dong H, Dutrow G, Evans JE, Graham J, Cummings BP, Havel PJ, Chiamvimonvat N, Despa S, Hammock BD, Despa F. Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats. Am J Physiol Heart Circ Physiol. 2012;303:H853-H862.
25. Oliw EH. Oxygenation of polyunsaturated fatty acids by cytochrome P450 monooxygenases. Prog Lipid Res. 1994;33:329-354.
26. Fitzpatrick FA, Ennis MD, Baze ME, Wynalda MA, McGee JE, Liggett WF. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids: influence of stereochemistry. J Biol Chem. 1986;261:15334-15338.
27. Spector AA, Fang X, Snyder GD, Weintraub NL. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res. 2004;43: 55-90.
28. Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res. 2005;44:1-51.
29. Luo P, Chang HH, Zhou Y, Zhang S, Hwang SH, Morisseau C, Wang CY, Inscho EW, Hammock BD, Wang MH. Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther. 2010;334:430-438.
30. Luria A, Bettaieb A, Xi Y, Shieh GJ, Liu HC, Inoue H, Tsai HJ, Imig JD, Haj FG, Hammock BD. Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci USA. 2011;108:9038-9043.
31. Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev. 2012;92:101-130.
32. Matveyenko AV, Butler PC. Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes. Diabetes. 2006;55:2106-2114.
33. Jones PD, Tsai HJ, Do ZN, Morisseau C, Hammock BD. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006;16:5212-5216.
34. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation. 1998;97:2316-2322.
35. Despa S, Bers DM, Despa F. Accumulation of islet amyloid polypeptide (IAPP) oligomers in the heart in type 2 diabetes alters Ca cycling in myocytes. Circulation. 2010;122:A18345, Abstract.
36. Lebeche D, Davidoff AJ, Hajjar RJ. Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat Clin Pract Cardiovasc Med. 2008;5:715-724.
37. 2+-cycling proteins may underlie sarcoplasmic reticulum dysfunction in the diabetic heart. Diabetes. 2001;50:2133-2138.
38. 2+]i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes. 2006;55:608-615.
39. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333-366.
40. Pattison JS, Sanbe A, Maloyan A, Osinska H, Klevitsky R, Robbins J. Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation. 2008;117:2743-2751.
41. Gianni D, Li A, Tesco G, McKay KM, Moore J, Raygor K, Rota M, Gwathmey JK, Dec GW, Aretz T, Leri A, Semigran MJ, Anversa P, Macgillivray TE, Tanzi RE, Del Monte F. Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy. Circulation. 2010;121:1216-1226.
42. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA. 1990;87:5036-5040.
43. Huang CJ, Haataja L, Gurlo T, Butler AE, Wu X, Soeller WC, Butler PC. Induction of endoplasmic reticulum stress-induced beta-cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide. Am J Physiol Endocrinol Metab. 2007;293:1656-1662.
44. Seward JB, Casaclang-Verzosa G. Infiltrative cardiovascular diseases: cardiomyopathies that look alike. J Am Coll Cardiol. 2010;55:1769-1779.
45. 2+-induced mitochondria permeability transition in normal and hypertrophied myocardium. J Pharmacol Exp Ther. 2010;335:155-162.